Fluorine in PDB 8tsc: Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3
Protein crystallography data
The structure of Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3, PDB code: 8tsc
was solved by
M.Holliday,
Y.Tang,
A.Bulku,
J.Wilbur,
J.Fraser,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
69.72 /
3.62
|
Space group
|
P 21 21 21
|
Cell size a, b, c (Å), α, β, γ (°)
|
85.561,
120.281,
190.445,
90,
90,
90
|
R / Rfree (%)
|
21.6 /
25.5
|
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3
(pdb code 8tsc). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total 4 binding sites of Fluorine where determined in the
Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3, PDB code: 8tsc:
Jump to Fluorine binding site number:
1;
2;
3;
4;
Fluorine binding site 1 out
of 4 in 8tsc
Go back to
Fluorine Binding Sites List in 8tsc
Fluorine binding site 1 out
of 4 in the Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 1 of Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3 within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1101
b:127.0
occ:1.00
|
F20
|
A:UJC1101
|
0.0
|
127.0
|
1.0
|
C19
|
A:UJC1101
|
1.4
|
107.4
|
1.0
|
C21
|
A:UJC1101
|
2.4
|
104.3
|
1.0
|
C18
|
A:UJC1101
|
2.4
|
106.4
|
1.0
|
HB3
|
A:LEU911
|
2.5
|
145.8
|
1.0
|
H181
|
A:UJC1101
|
2.6
|
129.5
|
1.0
|
HD12
|
A:LEU911
|
2.6
|
154.8
|
1.0
|
H211
|
A:UJC1101
|
2.6
|
127.0
|
1.0
|
HD22
|
A:LEU911
|
2.8
|
138.0
|
1.0
|
HG22
|
A:THR813
|
2.9
|
123.3
|
1.0
|
HD11
|
A:ILE913
|
3.3
|
150.4
|
1.0
|
CB
|
A:LEU911
|
3.4
|
120.0
|
1.0
|
HG13
|
A:ILE913
|
3.4
|
152.6
|
1.0
|
CD1
|
A:LEU911
|
3.4
|
127.5
|
1.0
|
CD2
|
A:LEU911
|
3.6
|
113.5
|
1.0
|
CG
|
A:LEU911
|
3.6
|
110.8
|
1.0
|
C17
|
A:UJC1101
|
3.6
|
115.6
|
1.0
|
C22
|
A:UJC1101
|
3.7
|
110.2
|
1.0
|
HG12
|
A:ILE913
|
3.7
|
152.6
|
1.0
|
CG2
|
A:THR813
|
3.7
|
101.3
|
1.0
|
OG1
|
A:THR813
|
3.7
|
113.6
|
1.0
|
HB2
|
A:LEU911
|
3.7
|
145.8
|
1.0
|
HA
|
A:THR813
|
3.8
|
123.5
|
1.0
|
HG21
|
A:THR813
|
3.8
|
123.3
|
1.0
|
CG1
|
A:ILE913
|
3.9
|
125.6
|
1.0
|
HZ
|
A:PHE1002
|
3.9
|
122.9
|
1.0
|
HD11
|
A:LEU911
|
4.0
|
154.8
|
1.0
|
HD13
|
A:LEU911
|
4.0
|
154.8
|
1.0
|
CD1
|
A:ILE913
|
4.1
|
123.8
|
1.0
|
HD23
|
A:LEU911
|
4.1
|
138.0
|
1.0
|
C23
|
A:UJC1101
|
4.1
|
121.7
|
1.0
|
CB
|
A:THR813
|
4.2
|
107.6
|
1.0
|
HD21
|
A:LEU911
|
4.2
|
138.0
|
1.0
|
O
|
A:LEU911
|
4.4
|
108.2
|
1.0
|
HG1
|
A:THR813
|
4.4
|
138.1
|
1.0
|
HG23
|
A:THR813
|
4.4
|
123.3
|
1.0
|
HE1
|
A:PHE1002
|
4.5
|
116.2
|
1.0
|
CA
|
A:THR813
|
4.5
|
101.3
|
1.0
|
CA
|
A:LEU911
|
4.6
|
114.2
|
1.0
|
HD13
|
A:ILE913
|
4.6
|
150.4
|
1.0
|
HG
|
A:LEU911
|
4.6
|
134.8
|
1.0
|
H141
|
A:UJC1101
|
4.6
|
150.2
|
1.0
|
HA
|
A:LEU911
|
4.6
|
138.8
|
1.0
|
CZ
|
A:PHE1002
|
4.7
|
100.9
|
1.0
|
HD12
|
A:ILE913
|
4.7
|
150.4
|
1.0
|
C15
|
A:UJC1101
|
4.9
|
110.6
|
1.0
|
C
|
A:LEU911
|
4.9
|
118.6
|
1.0
|
C24
|
A:UJC1101
|
4.9
|
105.5
|
1.0
|
CE1
|
A:PHE1002
|
5.0
|
95.3
|
1.0
|
HD21
|
A:LEU938
|
5.0
|
132.7
|
1.0
|
|
Fluorine binding site 2 out
of 4 in 8tsc
Go back to
Fluorine Binding Sites List in 8tsc
Fluorine binding site 2 out
of 4 in the Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 2 of Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3 within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1101
b:106.0
occ:1.00
|
F25
|
A:UJC1101
|
0.0
|
106.0
|
1.0
|
C24
|
A:UJC1101
|
1.4
|
105.5
|
1.0
|
F26
|
A:UJC1101
|
2.2
|
94.9
|
1.0
|
F27
|
A:UJC1101
|
2.2
|
230.8
|
1.0
|
HA
|
A:GLN809
|
2.4
|
140.7
|
1.0
|
C22
|
A:UJC1101
|
2.4
|
110.2
|
1.0
|
H211
|
A:UJC1101
|
2.6
|
127.0
|
1.0
|
HB3
|
A:GLN809
|
2.8
|
139.5
|
1.0
|
C21
|
A:UJC1101
|
2.8
|
104.3
|
1.0
|
HG3
|
A:GLN809
|
2.9
|
138.6
|
1.0
|
CA
|
A:GLN809
|
3.1
|
115.7
|
1.0
|
HB3
|
A:LEU812
|
3.1
|
119.8
|
1.0
|
HG1
|
A:THR813
|
3.2
|
138.1
|
1.0
|
CB
|
A:GLN809
|
3.2
|
114.7
|
1.0
|
HD21
|
A:LEU812
|
3.2
|
131.6
|
1.0
|
O
|
A:GLN809
|
3.2
|
114.0
|
1.0
|
CG
|
A:GLN809
|
3.4
|
114.0
|
1.0
|
OG1
|
A:THR813
|
3.6
|
113.6
|
1.0
|
C
|
A:GLN809
|
3.6
|
113.6
|
1.0
|
HG2
|
A:GLN809
|
3.6
|
138.6
|
1.0
|
C23
|
A:UJC1101
|
3.6
|
121.7
|
1.0
|
H231
|
A:UJC1101
|
3.9
|
147.8
|
1.0
|
H
|
A:THR813
|
4.0
|
105.8
|
1.0
|
CB
|
A:LEU812
|
4.1
|
98.3
|
1.0
|
CD2
|
A:LEU812
|
4.1
|
108.2
|
1.0
|
HG
|
A:LEU812
|
4.1
|
127.3
|
1.0
|
HB2
|
A:GLN809
|
4.2
|
139.5
|
1.0
|
C19
|
A:UJC1101
|
4.2
|
107.4
|
1.0
|
CG
|
A:LEU812
|
4.4
|
104.5
|
1.0
|
N
|
A:GLN809
|
4.4
|
102.1
|
1.0
|
SD
|
A:MET1010
|
4.5
|
131.8
|
1.0
|
N
|
A:THR813
|
4.5
|
86.6
|
1.0
|
O
|
A:ARG808
|
4.5
|
116.5
|
1.0
|
HB2
|
A:LEU812
|
4.5
|
119.8
|
1.0
|
HD23
|
A:LEU812
|
4.6
|
131.6
|
1.0
|
HD21
|
A:LEU938
|
4.7
|
132.7
|
1.0
|
HE1
|
A:PHE1002
|
4.7
|
116.2
|
1.0
|
HD22
|
A:LEU812
|
4.7
|
131.6
|
1.0
|
HB2
|
A:GLU1012
|
4.8
|
127.7
|
1.0
|
C17
|
A:UJC1101
|
4.8
|
115.6
|
1.0
|
H
|
A:LEU812
|
4.8
|
138.1
|
1.0
|
CD
|
A:GLN809
|
4.8
|
111.1
|
1.0
|
HG2
|
A:GLU1012
|
4.8
|
158.2
|
1.0
|
HD12
|
A:LEU1013
|
4.8
|
136.2
|
1.0
|
HG
|
A:LEU938
|
4.8
|
159.4
|
1.0
|
H
|
A:GLN809
|
4.9
|
124.4
|
1.0
|
HD11
|
A:LEU1013
|
4.9
|
136.2
|
1.0
|
CB
|
A:THR813
|
4.9
|
107.6
|
1.0
|
C
|
A:ARG808
|
4.9
|
112.5
|
1.0
|
N
|
A:ASP810
|
4.9
|
108.8
|
1.0
|
HD22
|
A:LEU938
|
4.9
|
132.7
|
1.0
|
|
Fluorine binding site 3 out
of 4 in 8tsc
Go back to
Fluorine Binding Sites List in 8tsc
Fluorine binding site 3 out
of 4 in the Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 3 of Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3 within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1101
b:94.9
occ:1.00
|
F26
|
A:UJC1101
|
0.0
|
94.9
|
1.0
|
C24
|
A:UJC1101
|
1.4
|
105.5
|
1.0
|
F27
|
A:UJC1101
|
2.2
|
230.8
|
1.0
|
F25
|
A:UJC1101
|
2.2
|
106.0
|
1.0
|
C22
|
A:UJC1101
|
2.4
|
110.2
|
1.0
|
HD21
|
A:LEU812
|
2.5
|
131.6
|
1.0
|
HD11
|
A:LEU1013
|
2.8
|
136.2
|
1.0
|
HD12
|
A:LEU1013
|
2.9
|
136.2
|
1.0
|
H231
|
A:UJC1101
|
3.2
|
147.8
|
1.0
|
C23
|
A:UJC1101
|
3.2
|
121.7
|
1.0
|
CD1
|
A:LEU1013
|
3.3
|
112.0
|
1.0
|
C21
|
A:UJC1101
|
3.3
|
104.3
|
1.0
|
CD2
|
A:LEU812
|
3.4
|
108.2
|
1.0
|
H211
|
A:UJC1101
|
3.4
|
127.0
|
1.0
|
HB2
|
A:GLU1012
|
3.5
|
127.7
|
1.0
|
HD23
|
A:LEU812
|
3.5
|
131.6
|
1.0
|
HE1
|
A:PHE1002
|
3.6
|
116.2
|
1.0
|
HG3
|
A:GLN809
|
3.8
|
138.6
|
1.0
|
HG
|
A:LEU1013
|
3.9
|
135.2
|
1.0
|
HD22
|
A:LEU812
|
3.9
|
131.6
|
1.0
|
HB3
|
A:LEU812
|
4.0
|
119.8
|
1.0
|
HA
|
A:GLN809
|
4.0
|
140.7
|
1.0
|
HD13
|
A:LEU1013
|
4.0
|
136.2
|
1.0
|
SD
|
A:MET1010
|
4.1
|
131.8
|
1.0
|
HB3
|
A:GLU1012
|
4.1
|
127.7
|
1.0
|
HG
|
A:LEU812
|
4.2
|
127.3
|
1.0
|
CB
|
A:GLU1012
|
4.2
|
104.9
|
1.0
|
CG
|
A:LEU1013
|
4.2
|
111.1
|
1.0
|
CG
|
A:LEU812
|
4.3
|
104.5
|
1.0
|
H353
|
A:UJC1101
|
4.3
|
153.1
|
1.0
|
HD1
|
A:PHE1002
|
4.4
|
108.8
|
1.0
|
H352
|
A:UJC1101
|
4.4
|
153.1
|
1.0
|
HG2
|
A:GLU1012
|
4.5
|
158.2
|
1.0
|
HE1
|
A:MET1010
|
4.5
|
133.8
|
1.0
|
C17
|
A:UJC1101
|
4.5
|
115.6
|
1.0
|
CE1
|
A:PHE1002
|
4.5
|
95.3
|
1.0
|
CG
|
A:GLN809
|
4.5
|
114.0
|
1.0
|
C19
|
A:UJC1101
|
4.6
|
107.4
|
1.0
|
HB3
|
A:MET1010
|
4.6
|
254.2
|
1.0
|
HE2
|
A:MET1010
|
4.6
|
133.8
|
1.0
|
HG2
|
A:GLN809
|
4.6
|
138.6
|
1.0
|
CB
|
A:LEU812
|
4.6
|
98.3
|
1.0
|
CE
|
A:MET1010
|
4.7
|
110.0
|
1.0
|
HB3
|
A:GLN809
|
4.7
|
139.5
|
1.0
|
CG
|
A:GLU1012
|
4.8
|
130.3
|
1.0
|
OE1
|
A:GLU1012
|
4.8
|
127.5
|
1.0
|
C35
|
A:UJC1101
|
4.8
|
126.0
|
1.0
|
CD1
|
A:PHE1002
|
4.9
|
89.1
|
1.0
|
HD21
|
A:LEU1013
|
4.9
|
166.2
|
1.0
|
CA
|
A:GLN809
|
4.9
|
115.7
|
1.0
|
HB2
|
A:LEU812
|
4.9
|
119.8
|
1.0
|
CB
|
A:GLN809
|
5.0
|
114.7
|
1.0
|
|
Fluorine binding site 4 out
of 4 in 8tsc
Go back to
Fluorine Binding Sites List in 8tsc
Fluorine binding site 4 out
of 4 in the Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3
Mono view
Stereo pair view
|
A full contact list of Fluorine with other atoms in the F binding
site number 4 of Human PI3K P85ALPHA/P110ALPHA H1047R Bound to Compound 3 within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:F1101
b:230.8
occ:1.00
|
F27
|
A:UJC1101
|
0.0
|
230.8
|
1.0
|
C24
|
A:UJC1101
|
1.4
|
105.5
|
1.0
|
F26
|
A:UJC1101
|
2.2
|
94.9
|
1.0
|
F25
|
A:UJC1101
|
2.2
|
106.0
|
1.0
|
C22
|
A:UJC1101
|
2.4
|
110.2
|
1.0
|
HG3
|
A:GLN809
|
2.5
|
138.6
|
1.0
|
H231
|
A:UJC1101
|
2.6
|
147.8
|
1.0
|
HG2
|
A:GLN809
|
2.7
|
138.6
|
1.0
|
HG2
|
A:GLU1012
|
2.7
|
158.2
|
1.0
|
HB2
|
A:GLU1012
|
2.8
|
127.7
|
1.0
|
C23
|
A:UJC1101
|
2.8
|
121.7
|
1.0
|
CG
|
A:GLN809
|
3.0
|
114.0
|
1.0
|
CG
|
A:GLU1012
|
3.3
|
130.3
|
1.0
|
CB
|
A:GLU1012
|
3.3
|
104.9
|
1.0
|
HB3
|
A:GLN809
|
3.3
|
139.5
|
1.0
|
HB3
|
A:GLU1012
|
3.4
|
127.7
|
1.0
|
CD
|
A:GLU1012
|
3.4
|
125.3
|
1.0
|
OE1
|
A:GLU1012
|
3.4
|
127.5
|
1.0
|
HG
|
A:LEU938
|
3.5
|
159.4
|
1.0
|
CB
|
A:GLN809
|
3.7
|
114.7
|
1.0
|
C21
|
A:UJC1101
|
3.7
|
104.3
|
1.0
|
HA
|
A:GLN809
|
3.7
|
140.7
|
1.0
|
H211
|
A:UJC1101
|
3.9
|
127.0
|
1.0
|
HE21
|
A:GLN809
|
4.0
|
128.6
|
1.0
|
HG3
|
A:GLU1012
|
4.2
|
158.2
|
1.0
|
C17
|
A:UJC1101
|
4.2
|
115.6
|
1.0
|
OE2
|
A:GLU1012
|
4.2
|
132.1
|
1.0
|
CA
|
A:GLN809
|
4.2
|
115.7
|
1.0
|
CD
|
A:GLN809
|
4.3
|
111.1
|
1.0
|
HD12
|
A:LEU1013
|
4.3
|
136.2
|
1.0
|
HD21
|
A:LEU938
|
4.3
|
132.7
|
1.0
|
HD21
|
A:LEU812
|
4.4
|
131.6
|
1.0
|
CG
|
A:LEU938
|
4.4
|
131.3
|
1.0
|
HB3
|
A:MET1010
|
4.4
|
254.2
|
1.0
|
HB2
|
A:GLN809
|
4.5
|
139.5
|
1.0
|
HD22
|
A:LEU938
|
4.5
|
132.7
|
1.0
|
SD
|
A:MET1010
|
4.5
|
131.8
|
1.0
|
NE2
|
A:GLN809
|
4.6
|
105.6
|
1.0
|
CD2
|
A:LEU938
|
4.7
|
109.0
|
1.0
|
H
|
A:GLU1012
|
4.7
|
138.2
|
1.0
|
HD11
|
A:LEU1013
|
4.7
|
136.2
|
1.0
|
CA
|
A:GLU1012
|
4.8
|
117.2
|
1.0
|
HD11
|
A:LEU938
|
4.8
|
146.9
|
1.0
|
C19
|
A:UJC1101
|
4.8
|
107.4
|
1.0
|
H352
|
A:UJC1101
|
4.8
|
153.1
|
1.0
|
O16
|
A:UJC1101
|
4.8
|
164.5
|
1.0
|
CD1
|
A:LEU1013
|
5.0
|
112.0
|
1.0
|
HG
|
A:LEU1013
|
5.0
|
135.2
|
1.0
|
|
Reference:
A.Varkaris,
E.Pazolli,
H.Gunaydin,
Q.Wang,
L.Pierce,
A.A.Boezio,
L.Dipietro,
A.Frost,
F.Giordanetto,
E.P.Hamilton,
K.Harris,
M.Holliday,
T.L.Hunter,
A.Iskandar,
Y.Ji,
A.Larivee,
J.R.Larochelle,
A.Lescarbeau,
F.Llambi,
B.Lormil,
M.M.Mader,
B.G.Mar,
I.Martin,
T.H.Mclean,
K.Michelsen,
Y.Pechersky,
E.Puente-Poushnejad,
R.Samadani,
A.M.Schram,
K.Shortsleeves,
S.Swaminathan,
S.Tajmir,
G.Tan,
Y.Tang,
R.Valverde,
B.Wehrenberg,
J.Wilbur,
B.R.Williams,
H.Zeng,
W.P.Walters,
B.B.Wolf,
D.E.Shaw,
D.A.Bergstrom,
J.Watters,
J.S.Fraser,
P.D.Fortin,
D.R.Kipp.
Discovery and Clinical Proof-of-Concept of Rly-2608, A First-in-Class Mutant-Selective Allosteric PI3KA Inhibitor That Decouples Anti-Tumor Activity From Hyperinsulinemia. Cancer Discov 2023.
ISSN: ESSN 2159-8290
PubMed: 37916956
DOI: 10.1158/2159-8290.CD-23-0944
Page generated: Sat Aug 3 00:42:56 2024
|